Merek & Company 13F Filing Shows Co Reported 1.214M-Share Position In Evaxion Valued At $3.76M

Evaxion Announces Expansion Of AI-Immunology Platform Into Autoimmune Diseases, Begins Experimental Testing Of Tolerogenic Vaccine And Autoantibody Binder Concepts; Initial Data Due At PEGS Europe November 18

Merck, Daiichi Sankyo Voluntarily Withdraw Biologics License Application Approval In U.S. For Ifinatamab Deruxtecan To Treat Small Cell Lung Cancer After Discussions With FDA

The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck’s (NYSE: MRK), known as MSD outside of the United States and Canada, ifinatamab deruxtecan

AMD Hits $1 Trillion, Muse Spooks Subscription Stocks: This Week on Wall Street

AMD crossed $1 trillion and Meta's Muse rattled subscription stocks. Meanwhile, Treasury yields hit 2007 highs.

Merck Receives FDA Approval For Its Dual Oral Regimen Of WELIREG Plus LENMIVA For The Treatment Of Adult Patients With Advanced Renal Cell Carcinoma With A Clear Cell Component

U.S. Food and Drug Administration (FDA) has approved the dual oral regimen of WELIREG® (belzutifan), Merck’s first-in-class oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, plus LENVIMA® (lenvatinib), the

Why is Moderna (MRNA) Stock Trending After Hours?

Moderna shares rose 0.09% after hours Thursday as investors eyed upcoming oncology data at a major European conference.